Isotretinoin therapy for recurrent respiratory papillomatosis

Arch Otolaryngol Head Neck Surg. 1994 Apr;120(4):405-9. doi: 10.1001/archotol.1994.01880280033005.

Abstract

Retinoic acid has been advocated for use in several premalignant and malignant epithelial lesions of the head and neck, including benign recurrent respiratory papillomatosis, with varying results. We describe a 24-year-old man with extensive tracheoesophageal and bronchoalveolar papillomatosis that degenerated into squamous cell carcinoma. Multiple endoscopic carbon dioxide laser excisions, at one point performed on a weekly basis, as well as a prolonged trial of interferon, failed to control the progression of his disease. Isotretinoin (13-cis-retinoic acid) therapy (1 mg/kg per day) was instituted, with dramatic clinical, radiographic, and functional improvement. The patient experienced no significant toxic effects and required no endoscopic procedures over a 6-month period. We propose that isotretinoin may be an effective adjuvant therapy for aggressive respiratory papillomatosis.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Carcinoma, Squamous Cell / pathology
  • Humans
  • Isotretinoin / administration & dosage*
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasms, Multiple Primary / diagnostic imaging
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / pathology
  • Papilloma / diagnostic imaging
  • Papilloma / drug therapy*
  • Papilloma / pathology
  • Radiography
  • Respiratory Tract Neoplasms / diagnostic imaging
  • Respiratory Tract Neoplasms / drug therapy*
  • Respiratory Tract Neoplasms / pathology

Substances

  • Isotretinoin